[{"orgOrder":0,"company":"Universiti Kebangsaan Malaysia Medical Centre","sponsor":"Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MALAYSIA","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Universiti Kebangsaan Malaysia Medical Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universiti Kebangsaan Malaysia Medical Centre \/ Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia","highestDevelopmentStatusID":"1","companyTruncated":"Universiti Kebangsaan Malaysia Medical Centre \/ Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia"},{"orgOrder":0,"company":"University of Zagreb","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"CROATIA","productType":"Probiotic","year":"2016","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Dental and Oral Health","graph2":"Phase IV","graph3":"University of Zagreb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"University of Zagreb \/ BioGaia Pharma","highestDevelopmentStatusID":"11","companyTruncated":"University of Zagreb \/ BioGaia Pharma"},{"orgOrder":0,"company":"Centre Hospitalier Intercommunal Creteil","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Centre Hospitalier Intercommunal Creteil","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Centre Hospitalier Intercommunal Creteil \/ BioGaia Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Centre Hospitalier Intercommunal Creteil \/ BioGaia Pharma"},{"orgOrder":0,"company":"Sisters of Mercy University Hospital","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Neurology","graph2":"Phase III","graph3":"Sisters of Mercy University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sisters of Mercy University Hospital \/ BioGaia Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Sisters of Mercy University Hospital \/ BioGaia Pharma"},{"orgOrder":0,"company":"Linkoeping University","sponsor":"BioGaia Pharma | The Ekhaga Foundation, Sweden | The Heart and Lung foundation, Sweden | The Research Council for the South-East Sweden | The Swedish Asthma and Allergy Association, Sweden | The Swedish Research Council | University Hospital, Linkoeping","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Probiotic","year":"2011","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Immunology","graph2":"Phase II","graph3":"Linkoeping University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Linkoeping University \/ BioGaia Pharma | The Ekhaga Foundation, Sweden | The Heart and Lung foundation, Sweden | The Research Council for the South-East Sweden | The Swedish Asthma and Allergy Association, Sweden | The Swedish Research Council | University Hospital, Linkoeping","highestDevelopmentStatusID":"8","companyTruncated":"Linkoeping University \/ BioGaia Pharma | The Ekhaga Foundation, Sweden | The Heart and Lung foundation, Sweden | The Research Council for the South-East Sweden | The Swedish Asthma and Allergy Association, Sweden | The Swedish Research Council | University Hospital, Linkoeping"},{"orgOrder":0,"company":"Ostergotland County Council","sponsor":"BioGaia Pharma | Ekhaga Foundation, Sweden | Medical Research Council of Southeast Sweden | University Hospital, Linkoeping | The Swedish Research Council | Swedish Society of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ostergotland County Council","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ostergotland County Council \/ BioGaia Pharma | Ekhaga Foundation, Sweden | Medical Research Council of Southeast Sweden | University Hospital, Linkoeping | The Swedish Research Council | Swedish Society of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Ostergotland County Council \/ BioGaia Pharma | Ekhaga Foundation, Sweden | Medical Research Council of Southeast Sweden | University Hospital, Linkoeping | The Swedish Research Council | Swedish Society of Medicine"},{"orgOrder":0,"company":"NovoNatum Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"NovoNatum Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovoNatum Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NovoNatum Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Atlantia Food Clinical Trials | CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Atlantia Food Clinical Trials | CTC Clinical Trial Consultants","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Atlantia Food Clinical Trials | CTC Clinical Trial Consultants"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infant Bacterial Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Infant Bacterial Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Children's Investigational Research Program, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Children's Investigational Research Program, LLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Children's Investigational Research Program, LLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Children's Investigational Research Program, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Case Western Reserve University","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Case Western Reserve University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Case Western Reserve University \/ BioGaia Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Case Western Reserve University \/ BioGaia Pharma"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"||Bacteria microbiome","graph1":"Neurology","graph2":"Phase I","graph3":"Scioto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scioto Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Scioto Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Genome & Company","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Series B Financing","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Scioto Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Scioto Biosciences \/ Genome & Company","highestDevelopmentStatusID":"7","companyTruncated":"Scioto Biosciences \/ Genome & Company"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"||Bacteria microbiome","graph1":"Neurology","graph2":"Phase I","graph3":"Scioto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scioto Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Scioto Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"BioGaia Pharma","sponsor":"Vastra Gotaland Region","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Probiotic","year":"2013","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"BioGaia Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGaia Pharma \/ Vastra Gotaland Region","highestDevelopmentStatusID":"1","companyTruncated":"BioGaia Pharma \/ Vastra Gotaland Region"}]
Find Clinical Drug Pipeline Developments & Deals for Lactobacillus Reuteri
Details :
IBP-1016 (lactobacillus reuteri) is known to have four interactive mechanisms of action that is gut microbiome and receives FDA orphan drug designation for gastroschisis.
Details :
IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for prevention of necrotizing entercolitis (NEC) and sustained feeding tolerance (SFT) among premature infants.
Details :
IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for prevention of Necrotizing Entercolitis (NEC) and sustained feeding tolerance (SFT) among premature infants.
Details :
SB-121 is a novel formulation of Lactobacillus reuteri (Lr) and was given to patients 15 to 45 years of age diagnosed with ASD. With the results now published, the study demonstrated that SB-121 was safe and well-tolerated.
Details :
IBP-9414 for the prevention of necrotizing enterocolitis contains the active substance lactobacillus reuteri, known to be anti-inflammatory, anti-pathogenic and beneficial to gut motility. It is a co-evolved human bacterial strain naturally present in br...
Details :
IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for gastroschisis (a severe and rare disease affecting infants), to prevent ROP and to prevent antibiotic resistant hospital acqui...
Details :
IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk,become the world’s first approved probiotical drug with the goal to prevent life threatening diseases in premature infants.
Details :
Lactobacillus Reuteri is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Helicobacter Infections.